Miconazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Miconazole: From Fungal Infections to Acne
One-Sentence Summary
Miconazole is an imidazole-class antifungal, with its specific approved indications not on file due to the drug currently being unmarketed in New Zealand. The TxGNN model predicts it may be effective for Acne, but this direction is currently supported only by 1 low-relevance clinical trial and 4 publications, none of which directly test miconazole in acne patients.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — Miconazole is not currently marketed in New Zealand and no approved indication text is on file (general class use: antifungal/fungal infections) |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L4 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Miconazole is part of the imidazole antifungal class, its efficacy in fungal infections has been proven, and mechanistically may be applicable to acne.
The repurposing rationale rests on in vitro evidence that miconazole (and related azole antifungals) inhibit Propionibacterium acnes, the bacterium implicated in acne pathogenesis, alongside literature describing miconazole's broader antimicrobial and possible anti-inflammatory effects on skin lesions. This provides biological plausibility for a link between an antifungal agent and an inflammatory skin condition traditionally treated with antibiotics.
However, this plausibility has not yet been tested directly: no identified clinical trial administers miconazole specifically for acne, and the supporting literature consists largely of in vitro, review, and tangentially related clinical studies rather than acne-specific interventional data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01244256 | Phase 2/3 | Suspended | 80 | Compared a topical cream combining beclomethasone + gentamicin + clotrimazole (not miconazole) in patients with contaminated dermatosis/acne-like lesions. Relevance graded C — different azole drug, suspended trial, low direct relevance to miconazole. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18627330 | 2008 | Review | Expert Opinion on Pharmacotherapy | Reviews miconazole's multifaceted effects on skin disorders beyond simple antifungal activity |
| 20045949 | 2010 | In vitro | Biological & Pharmaceutical Bulletin | Azole antifungal agents, including miconazole-class compounds, show in vitro inhibitory activity against P. acnes isolated from acne vulgaris patients |
| 15536660 | 2004 | Clinical (split-face) | Skin Research and Technology | Assesses catamenial acne management; direct relevance to miconazole is unclear |
| 8593718 | 1995 | Cohort/therapeutic trial | Clinical and Experimental Dermatology | Evaluates Pityrosporum (Malassezia) folliculitis, a condition often misdiagnosed as acne vulgaris — not the same disease entity |
New Zealand Market Information
Currently no market authorization records available — Miconazole is not marketed in New Zealand (0 authorizations on file).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to in vitro antibacterial activity against P. acnes and indirect/review literature; the only registered clinical trial tested a different azole (clotrimazole) and was suspended, so there is no direct clinical evidence supporting miconazole for acne (Evidence Level L4, Decision Stage S0).
To proceed, the following is needed:
- TFDA/Medsafe package insert data — warnings and contraindications (currently a Blocking data gap, DG001)
- Confirmed mechanism of action data for miconazole (DG002)
- A dedicated clinical trial or pilot study testing miconazole (not related azoles) directly in acne patients
- Basic drug interaction (DDI) profile, currently unavailable
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.